共查询到20条相似文献,搜索用时 62 毫秒
1.
新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)是近期在世界范围发生的一种以呼吸系统症状为主要表现的传染性疾病,该病对我国乃至世界人民的生命安全造成了重大威胁。严重急性呼吸综合征冠状病毒2(Severe Acute Respiratory Syndrome Coronavirus 2,SARS-CoV-2)的传染性较SARS-CoV、MERS-CoV强,是该病原体最大特点之一,且其感染后进展快、危害大。现已经过我国及全世界科学家努力对该病有了进一步的认识。该文旨在对该病的认识进行梳理,提高临床医生对该病的初步认识。 相似文献
2.
3.
4.
新型冠状病毒肺炎(Coronavirus Disease 2019,COVID 19)是指2019新型冠状病毒(Severe Acute Respiratory Syndrome Coronavirus 2,SARS CoV 2)感染导致的肺炎。截至2020年5月21日已造成全球超过496万人感染、30万人以上死亡。宏基因组下一代测序(metagenomic next generation sequencing,mNGS)技术是在发现和检测新冠肺炎中发挥重要作用的技术。本文介绍了mNGS在新冠肺炎疫情中的作用及核心技术特点,并为mNGS在抗击全球疫情中的应用做出技术性归纳总结。 相似文献
5.
根据现有的数据,新型冠状病毒(2019 novel coronavirus,2019-nCoV)比严重急性呼吸综合征冠状病毒(severe acute respiratory syndrome coronavirus,SARS-CoV)的传染性强、传播速度快、疫情规模大、病死率低。其传染性、传播速度和疫情规模似乎具有甲型流感病毒(influenza A virus)的特点。尽管2019-nCoV来源于何种动物尚无定论,但它与SARS-CoV同属冠状病毒,具有共同之处。如果流行过后 2019-nCoV没能在人群中持续传播和存在(如同SARS-CoV一样),则控制野生动物传染源乃重中之重;如果2019-nCoV获得了能在人群中持续传播的能力,预防控制策略将与SARS-CoV明显不同,疫苗便成为至关重要的手段。 相似文献
6.
新型冠状病毒肺炎(corona virus disease 2019, COVID-19)是指由新型冠状病毒(severe acute respiratory syndrome coronavirus2, SARS-CoV-2)感染导致的肺炎。SARS-CoV-2结合细胞表面受体——血管紧张素转化酶2 (angiotensin-converting enzyme 2,ACE2)感染肺部细胞,导致白细胞浸润,血管和肺泡壁通透性增加,肺表面活性物质减少,引起呼吸系统症状。局部的炎症加重引起细胞因子风暴,造成全身性炎症反应综合征。2019年12月,武汉市卫生健康委员会报告了多例新型肺炎,分离并确定了病原体SARS-CoV-2。截至2020年9月13日,全世界216个国家或地区受累,2 860余万人确诊COVID-19,90余万人死于该疾病,病死率高达3.20%。到目前为止,尚无特效药物可治疗COVID-19,因此解析病毒结构,探索治疗药物显得尤其重要。本文总结了SARS-CoV-2的病毒结构和COVID-19的临床药物治疗,并分析了他们之间可能的相关性。 相似文献
7.
8.
于永利 《微生物学免疫学进展》2021,(3):1-4
伴随着严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome-coronavirus 2,SARS-CoV-2)疫苗(也称COVID-19疫苗)在世界各地预防接种的展开,SARS-CoV-2突变株也在世界多地相继出现,其中有的突变株可能对现行SARS-CoV-2疫苗诱导的抗体产... 相似文献
9.
10.
严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)自被发现以来就引起了人们的广泛关注,开发针对该病毒的安全、有效疫苗成为近期的研究热点。本文以高致病性冠状病毒疫苗(包括灭活疫苗、重组亚单位疫苗、重组病毒载体疫苗和核酸疫苗)的研究展开综述,为研制SARS-CoV-2疫苗提供参考。 相似文献
11.
重组SARS冠状病毒刺突蛋白的表达和分离纯化 总被引:7,自引:1,他引:7
SARS冠状病毒的感染能引发人的严重急性呼吸综合征。根据对其他种类冠状病毒的研究结果 ,刺突(spike)蛋白 (S蛋白 )是病毒的主要表面抗原 ,重组S蛋白可用于临床诊治 ,疫苗制备和结构生物学研究。SARS病毒S蛋白基因被分段和完整地克隆到不同的细菌表达载体进行了表达。通过宿主菌的选择和条件的优化 ,其中75 1~ 192 5bp、2 0 0 5~ 3410bp、1~ 192 5bp、32~ 36 5 9bp片段及全长 1~ 376 8bpDNA都在大肠杆菌中实现了高效表达 ,表达量分别占菌体蛋白质的 35 %、34%、2 4 %、17%和 5 % ,并经亲和层析得到了部分纯化。纯化后的蛋白质将用于诊断试剂和结构生物学研究。 相似文献
12.
13.
重组SARS冠状病毒M蛋白的表达、纯化及鉴定 总被引:1,自引:0,他引:1
SARS冠状病毒是人的严重急性呼吸综合征的病原体。根据对其他种类冠状病毒的研究结果 ,膜蛋白 (M蛋白 )是病毒主要的结构蛋白 ,重组M蛋白可被用来作为抗原检测对应冠状病毒的感染和制备疫苗。SARS病毒M蛋白基因克隆到原核表达载体pMAL cRI中 ,利用N端和C端分别融合麦芽糖结合蛋白 (maltosebindingprotein和MxeGyrAinteinCBD的策略 ,在大肠杆菌中初步表达了重组M蛋白 ,并通过Western印迹和质谱对蛋白质进行了鉴定。重组蛋白质经亲和层析得到了部分纯化 ,纯化后的蛋白质将用于功能研究与诊断试剂盒的研制。 相似文献
14.
新型冠状病毒肺炎(2019 novel coronavirus disease,COVID-19),一种由动物来源的新型冠状病毒(severe acute respiratory syndrome coronavirus 2,SRAS-CoV-2)感染所致的疾病在全球范围内急速传播,严重的危害人类的健康.快速、准确的诊... 相似文献
15.
Aline
H. de Nooijer Inge Grondman Simon Lambden Emma
J. Kooistra Nico
A.F. Janssen Matthijs Kox Peter Pickkers Leo
A.B. Joosten Frank
L. van de Veerdonk Marc Derive Sebastien Gibot Mihai
G. Netea 《Bioscience reports》2021,41(7)
Patients with sepsis display increased concentrations of sTREM-1 (soluble Triggering Receptor Expressed on Myeloid cells 1), and a phase II clinical trial focusing on TREM-1 modulation is ongoing. We investigated whether sTREM-1 circulating concentrations are associated with the outcome of patients with coronavirus disease 2019 (COVID-19) to assess the role of this pathway in COVID-19. This observational study was performed in two independent cohorts of patients with COVID-19. Plasma concentrations of sTREM-1 were assessed after ICU admission (pilot cohort) or after COVID-19 diagnosis (validation cohort). Routine laboratory and clinical parameters were collected from electronic patient files. Results showed sTREM-1 plasma concentrations were significantly elevated in patients with COVID-19 (161 [129–196] pg/ml) compared to healthy controls (104 [75–124] pg/ml; P<0.001). Patients with severe COVID-19 needing ICU admission displayed even higher sTREM-1 concentrations compared to less severely ill COVID-19 patients receiving clinical ward-based care (235 [176–319] pg/ml and 195 [139–283] pg/ml, respectively, P = 0.017). In addition, higher sTREM-1 plasma concentrations were observed in patients who did not survive the infection (326 [207–445] pg/ml) compared to survivors (199 [142–278] pg/ml, P<0.001). Survival analyses indicated that patients with higher sTREM-1 concentrations are at higher risk for death (hazard ratio = 3.3, 95%CI: 1.4–7.8). In conclusion, plasma sTREM-1 concentrations are elevated in patients with COVID-19, relate to disease severity, and discriminate between survivors and non-survivors. This suggests that the TREM-1 pathway is involved in the inflammatory reaction and the disease course of COVID-19, and therefore may be considered as a therapeutic target in severely ill patients with COVID-19. 相似文献
16.
严重急性呼吸综合征(SARS)病毒的形态及其形态发生机制 总被引:8,自引:0,他引:8
张勤奋崔金明 黄小俊林伟谭冬艳 徐洁薇杨艺峰 张景强张欣 李晖郑焕英 陈秋霞鄢心革 郑夔万卓越 黄吉城 《Acta biochimica et biophysica Sinica》2003,35(6):587-591
将SARS患者的咽拭子感染VeroE6细胞 ,用电子显微技术等对SARS病毒进行了研究。结果表明 ,新分离到的病毒粒子没带囊膜时直径大多约 5 0nm ,带有囊膜的直径约 10 0nm。通过RT PCR等证明 ,该病毒是新的冠状病毒。这些病毒可与SARS康复患者的血清呈强烈的阳性反应 ,表明此新的冠状病毒是引起SARS的主要病原。文中还对病毒的发生机制和细胞中的分布进行了探讨。 相似文献
17.
COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large number of patients around the world. A hyperinflammatory state resulting in a cytokine storm and adult respiratory distress syndrome seems to be the major cause of the death. Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine storm (COVID-CS). Insufficient viral clearance and persistence of a strong cytokine response despite inadequate antiviral immunity seem to be the main mechanisms underlying the pathogenesis. The diagnosis of COVID-19 is based on relatively constant clinical symptoms, clinical findings, laboratory tests, and imaging techniques, while the diagnosis of COVID-CS is a rather dynamic process, based on evolving or newly emerging findings during the clinical course. Management of COVID-19 consists of using antiviral agents to inhibit SARS-CoV-2 replication and treating potential complications including the cytokine storm together with general supportive measures. COVID-CS may be treated using appropriate immunosuppressive and immunomodulatory drugs that reduce the level of inappropriate systemic inflammation, which has the potential to cause organ damage. Currently corticosteroids, IL-6 blockers, or IL-1 blockers are most widely used for treating COVID-CS. 相似文献
18.
Expression, purification and sublocalization of SARS-CoV nucleocapsid protein in insect cells 总被引:2,自引:0,他引:2
Ren AX Xie YH Kong YY Yang GZ Zhang YZ Wang Y Wu XF 《Acta biochimica et biophysica Sinica》2004,36(11):754-758
The causative agent of severe acute respiratory syndrome (SARS) is a previously unidentified coronavirus, SARS-CoV. The nucleocapsid (N) protein of SARS-CoV is a major viral protein recognized by acute and early convalescent sera from SARS patients. To facilitate the studies on the function and structure of the N protein, this report describe the expression and purification of recombinant SARS-CoV N protein using the baculovirus 相似文献
19.
Changfu Yao Stephanie A. Bora Tanyalak Parimon Tanzira Zaman Oren A. Friedman Joseph A. Palatinus Nirmala S. Surapaneni Yuri P. Matusov Giuliana Cerro Chiang Alexander G. Kassar Nayan Patel Chelsi E.R. Green Adam W. Aziz Harshpreet Suri Jo Suda Andres A. Lopez Gislâine A. Martins Barry R. Stripp Peter Chen 《Cell reports》2021,34(1):108590
20.
Koji Ishii Hideki Hasegawa Noriyo Nagata Yasushi Ami Shuetsu Fukushi Fumihiro Taguchi Yasuko Tsunetsugu-Yokota 《Microbiology and immunology》2009,53(2):75-82
We evaluated the efficacy of three SARS vaccine candidates in a murine SARS model utilizing low-virulence Pp and SARS-CoV coinfection. Vaccinated mice were protected from severe respiratory disease in parallel with a low virus titer in the lungs and a high neutralizing antibody titer in the plasma. Importantly, the administration of spike protein-specific neutralizing monoclonal antibody protected mice from the disease, indicating that the neutralization is sufficient for protection. Moreover, a high level of IL-6 and MCP-1 production, but not other 18 cytokines tested, on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity, suggesting the importance of these cytokines in the lung pathogenicity of SARS-CoV infection. 相似文献